THERAPIES FOR SEVERE HERPES VIRUS INFECTION

严重疱疹病毒感染的治疗

• 批准号: 2295081
• 负责人: RICHARD D WHITIEY
• 金额: $ 133.3万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1991
• 资助国家: 美国
• 起止时间: 1991-07-01 至 1996-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2295081
• 关键词: THERAPIES; SEVERE; HERPES; VIRUS; INFECTION

This contract is the major component of the Antiviral Research Branch's Clinical Trials program. The objectives are to evaluate experimental therapies for severe herpesvirus infections. Studies to be undertaken in the coming project period include: the evaluation of BVaraU for the treatment of shingles in patients who are immunosuppressed due to cancer chemotherapy or HIV infection, the evaluation of ganciclovir or a monoclonal antibody for the therapy of symptomatic congenital cytomegalovirus infection, suppressive acyclovir therapy for infants with localized neonatal herpes and herpes encephalitis. In addition, data on the natural history, immune response to and epidemiology of these diseases will be collected. A pilot study to determine the factors which influence the frequency of transmission of herpes simplex virus to the neonate at birth with continued.

该合同是抗病毒研究分部的主要组成部分 临床试验计划。目标是评估实验 治疗严重疱疹病毒感染。拟开展的研究 下一个项目期间包括： BVaraU 对 治疗因癌症而免疫抑制的患者的带状疱疹 化疗或 HIV 感染、更昔洛韦或其他药物的评估 用于治疗有症状的先天性疾病的单克隆抗体 巨细胞病毒感染，婴儿的阿昔洛韦抑制治疗 局限性新生儿疱疹和疱疹脑炎。此外，有关数据 这些疾病的自然史、免疫反应和流行病学将 被收集。一项试点研究以确定影响因素 新生儿出生时单纯疱疹病毒传播的频率 与继续。